Health
Phase 3 trials show AstraZeneca COVID vaccine has up to 90% efficacy – CIDRAP
The peer-reviewed data mirror unpublished results noted last month by the researchers, with up to 90% protection.
The first full peer-reviewed results of phase 3 trials of the COVID-19 vaccine developed by AstraZeneca and Oxford University show that it is safe and up to 90% effective in preventing infection, supporting regulatory submissions for emergency use.
The interim analysis, published today in The Lancet, identified no severe coronavirus disease or hospitalizations in pooled results from the 11,636 adults vaccinated in the United Kingdom and Brazil. Of the 11,636 adults, 131 (1.1%) had symptomatic COVID-19…
-
Noosa News24 hours agoWoman was watching keepers work when lion attacked, Darling Downs Zoo says
-
Noosa News23 hours agoWorking for someone else made it hard to care for my daughter. So I quit
-
General18 hours ago‘Potential’ hacker contacts Qantas over data breach
-
General23 hours agoReflections from a broken Europe